First-Line Camrelizumab Plus Rivoceranib in Advanced Hepatocellular Carcinoma: A China-Based Cost-Effectiveness Analysis.

Background: Hepatocellular carcinoma poses a significant public health burden in China, necessitating the economic evaluation of new therapeutic strategies for policy-makers and clinicians. The international, randomized phase 3 trial CARES-310 revealed that camrelizumab plus rivoceranib provided a s...

Full description

Bibliographic Details

Published in:	Clinical Medicine Insights: Oncology pp. 1 - 12
Main Authors:	Xiang, Guiyuan, Huang, Yueyue, Zhang, Ni, Du, Xinyu, Wu, Yuanlin, Gan, Lanlan, Li, Yanping, Jiang, Tingting, Liu, Yao
Format:	research tables/charts Journal Article
Published:	Sage Publications Inc. 11/23/2024
Online Access:	View this record in EBSCOhost